IP Library Granted Patent US 7,579,019
Granted Patent B2
US 7,579,019 · App. 11/069,089 · Granted Aug 25, 2009

Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,579,019
App. No.
11/069,089
Granted
Aug 25, 2009
Kind
B2
Abstract

The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.

Claims (10)

1. A method for the transmucosal delivery of a systemic pharmaceutical for achieving a fast onset of activity in a subject or a desired level of a systemic pharmaceutical in the blood of a subject, comprising:

adhering a bioerodable device to an oral mucosa surface of a subject such that there is minimal foreign body sensation; and

directionally delivering an amount of a systemic pharmaceutical from the bioerodable device to mucosal tissue of the subject such that an effective amount of the systemic pharmaceutical is delivered to the subject achieving a fast onset of activity in the subject or a desired level of the systemic pharmaceutical in the blood of the subject within about 30 minutes,

wherein the bioerodable device has a residence time of less than 1 hour or about 1 hour, and the device comprises a thin and flexible adherent and bioerodable polymeric film containing a systemic pharmaceutical, and wherein the bioerodable device comprises soluble polymers selected based on dissolution rates to achieve the desired residence time and release profile.

2. The method of claim 1 , comprising adhering the bioerodable device to a buccal mucosa surface.

3. The method of claim 1 , wherein the device has a residence time of less than 30 minutes or about 30 minutes.

4. The method of claim 1 , wherein the device has a thickness from about 0.1 mm and about 0.5 mm.

5. The method of claim 1 , wherein the device has a surface area of from about 0.5 to about 20 square centimeters.

6. The method of claim 1 , wherein the device further comprises a second pharmaceutical incorporated into the device.

7. The method of claim 1 , wherein the device instantaneously adheres to the mucosal surface upon application.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Dec 23, 2025
From: BIOPHARMA CREDIT PLC
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 073308/0246 →
SECURITY INTEREST Recorded Mar 22, 2022
From: BIODELIVERY SCIENCES INTERNATIONAL, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059340/0176 →
RELEASE OF SECURITY INTEREST Recorded Mar 22, 2022
From: BPCR LIMITED PARTNERSHIP
To: ARIUS TWO, INC.
Reel/Frame 059344/0583 →
RELEASE OF SECURITY INTEREST Recorded Mar 22, 2022
From: BPCR LIMITED PARTNERSHIP
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 059344/0733 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
SECURITY INTEREST Recorded May 15, 2020
From: BIODELIVERY SCIENCES INTERNATIONAL, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 052673/0903 →
SECURITY INTEREST Recorded May 29, 2019
From: ARIUS TWO, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 049305/0112 →